Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
MOU for organoid-based R&D with HLB Biostep and Biocode
24
2024.05
Kangstem Biotech signed a MOU(memorandum of understanding) with HLB BioStep and HLB BioCode on the 23rd to establish an organoid-based drug safety and efficacy evaluation platform and develop cell therapy drugs.
Kangstem Biotech signed a MOU(memorandum of understanding) with HLB BioStep and HLB BioCode on the 23rd to establish an organoid-based drug safety and efficacy evaluation platform and develop cell therapy drugs.
Through this MOU, the three companies plan to pursue the commercialization of animal replacement test methods using organoids in earnest. Kangstem Biotech will utilize skin and pancreatic organoid technology to build and commercialize an organoid-based evaluation platform that dramatically increases the predictive power of drug efficacy in humans with HLB BioStep. In addition, HLB BioCode's non-clinical toxicity evaluation capabilities will be utilized to develop alternative test methods for drug safety evaluation.
This will also accelerate the development of Kangstem Biotech's new pipeline of organoid therapeutics. The company will collaborate with HLB BioStep to seek early IND approval for a skin organoid-based hair loss treatment and a pancreatic organoid-based type 1 diabetes treatment.
As the three companies will work together based on their respective capabilities, including ▲ production and quality control of organoid technology and therapeutics, ▲ Korea's largest non-clinical efficacy evaluation, and ▲ non-clinical toxicity evaluation technology, the commercialization of organoid-using animal replacement test methods and R&D of the company's next-generation therapeutics, organoid-based hair loss and type 1 diabetes, are expected to accelerate.